NRG Therapeutics is a drug discovery company developing oral small molecule inhibitors targeting the mitochondrial permeability transition pore (mPTP) to restore mitochondrial function. The company aims to slow or halt the progression of neurodegenerative diseases such as Parkinson’s and Amyotrophic Lateral Sclerosis (ALS).
Funding
$28.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MJFounders
Product
Problem
Neurodegenerative diseases like Parkinson's and ALS are characterized by mitochondrial dysfunction, which contributes to neuronal damage and disease progression. Current treatments do not directly address this underlying mitochondrial impairment.
Solution
NRG Therapeutics is developing orally available, brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) to restore mitochondrial function in patients with neurodegenerative diseases. By inhibiting the mPTP, the company aims to prevent the release of mitochondrial DNA and the activation of cell death pathways, thereby slowing or halting the progression of diseases such as Parkinson's and ALS. Their approach targets the mitochondrial toxicity caused by misfolded proteins such as TDP-43 and α-synuclein, which are implicated in the degeneration of motor neurons and dopaminergic neurons. The company is advancing a pipeline of structurally differentiated chemical series with first-in-class potential.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases such as Parkinson's and ALS, as well as pharmaceutical companies seeking to expand their pipelines with novel therapeutic candidates.
Features
- Orally bioavailable and brain-penetrant small molecule mPTP inhibitors
- Novel mechanism of action for inhibiting the mPTP
- Prevention of mitochondrial DNA release, mitigating innate immune system activation
- Prevention of mitochondrial-mediated cell death induced by toxic α-synuclein
- Chemical series with structural differentiation